The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Hypereosinophilic Syndrome in Behcet’s Disease : Unearthing a Hidden Clonality


Affiliations
1 Empire Centre Haematology and Oncology Specialty Clinic, Bandra West, Mumbai, India
2 Dr Tahiliani’s Clinic, A-201/202, Gasper Enclave, Dr Ambedkar Road, Bandra West, Mumbai, India
3 Empire Centre Haematology and Oncology Specialty Clinic, Hill Road, Bandra West, Mumbai, India
     

   Subscribe/Renew Journal


The association of hypereosinophilic syndrome (HES) and Behcet’s disease is not well understood. Commonly, patients are treated with standard medications for hypereosinophilia, with variable responses. However, persistent hypereosinophilia (absolute eosinophilic count >1500 cells/μL) not responding to standard treatment may be predictive of a primary clonal haematological disorder. According to the revised World Health Organization (WHO) classification, HES has six categories; one of which is myeloproliferative neoplasm (clonal eosinophilia) associated with FIP1-like-1-platelet-derived growth factor receptor-alpha (FIP1L1-PDGFRα). We report a case of a 38-year-old Indian male with Behcet’s disease with concomitant HES, who tested positive for clonal eosinophilia (FIP1L1-PDGFRα fusion) which is a rare imatinib-sensitive mutation. The patient was administered low-dose imatinib mesylate (100 mg daily), and showed an excellent response with complete resolution of HES. The causal relationship between Bechet’s disease and HES requires further investigation and research. Left untreated, HES has the potential to cause severe end-organ damage and this necessitates early detection and treatment which can significantly reduce patient morbidity and mortality.

Keywords

Hypereosinophilia, FIP1L1-PDGFRα, Gene, Behcet’s Disease, Imatinib.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010 Jul;126(1):45-9.

  • Seifert M, Gerth J, Gajda M, Pester F, Pfeifer R, Wolf G. Eosinophilie--eine differentialdiagnostische Herausforderung [Eosinophilia--a challenging differential diagnosis]. Med Klin (Munich). 2008 Aug 15;103(8):591-7. German.

  • Sreedharanunni S, Varma N, Sachdeva MUS, Naseem S, Malhotra P, Bansal D, Trehan A, Varma S. The Spectrum of Hypereosinophilia and Associated Clonal Disorders - A Real-World Data Based on Combined Retrospective and Prospective Analysis from a Tropical Setting. Mediterr J Hematol Infect Dis. 2018 Sep 1;10(1):e2018052.

  • Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008 Nov;22(11):1999-2010.

  • Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004 Nov 15;104(10):3038-45.

  • Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982 Jul;97(1):78-92.

  • Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3.

  • Mashaleh MA, Burgan A, Khasawneh R, Khataybeh O, Kamal N, Heresh AA. Eosinophilic Leukemia Presenting with Behçet-Like Symptoms. Journal of the Royal Medicine Services. 2014;21(4):79-82.

  • Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9.

  • Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006 Aug;30(8):965-70.


Abstract Views: 123

PDF Views: 0




  • Hypereosinophilic Syndrome in Behcet’s Disease : Unearthing a Hidden Clonality

Abstract Views: 123  |  PDF Views: 0

Authors

Abhay Bhave
Empire Centre Haematology and Oncology Specialty Clinic, Bandra West, Mumbai, India
Nawal Kazi
Empire Centre Haematology and Oncology Specialty Clinic, Bandra West, Mumbai, India
Sushil Tahiliani
Dr Tahiliani’s Clinic, A-201/202, Gasper Enclave, Dr Ambedkar Road, Bandra West, Mumbai, India
Lakshmi Iyer
Empire Centre Haematology and Oncology Specialty Clinic, Hill Road, Bandra West, Mumbai, India

Abstract


The association of hypereosinophilic syndrome (HES) and Behcet’s disease is not well understood. Commonly, patients are treated with standard medications for hypereosinophilia, with variable responses. However, persistent hypereosinophilia (absolute eosinophilic count >1500 cells/μL) not responding to standard treatment may be predictive of a primary clonal haematological disorder. According to the revised World Health Organization (WHO) classification, HES has six categories; one of which is myeloproliferative neoplasm (clonal eosinophilia) associated with FIP1-like-1-platelet-derived growth factor receptor-alpha (FIP1L1-PDGFRα). We report a case of a 38-year-old Indian male with Behcet’s disease with concomitant HES, who tested positive for clonal eosinophilia (FIP1L1-PDGFRα fusion) which is a rare imatinib-sensitive mutation. The patient was administered low-dose imatinib mesylate (100 mg daily), and showed an excellent response with complete resolution of HES. The causal relationship between Bechet’s disease and HES requires further investigation and research. Left untreated, HES has the potential to cause severe end-organ damage and this necessitates early detection and treatment which can significantly reduce patient morbidity and mortality.

Keywords


Hypereosinophilia, FIP1L1-PDGFRα, Gene, Behcet’s Disease, Imatinib.

References